Product news from 11/18/05 News Brief

Share this article:

The FDA approved Roche and Genentech's Tarceva (erlotinib) for a new indication as a treatment for patients with advanced pancreatic cancer. Tarceva has previously been approved by the FDA as a treatment for lung cancer.

Reliant Pharmaceuticals announced the FDA has approved its Supplemental New Drug Application for a new dosing regimen and label change for the fenofibrate therapy Antara (fenofibrate capsules) 43 mg and 130 mg. The new regimen enables patients to take Antara 130 mg capsules with or without food, increasing convenience for the 15% of adults in the U.S. with elevated triglycerides.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Wednesday, August 20

Five things for pharma marketers to know: Wednesday, ...

Novartis explores the virtual care space, a court has dismissed a lawsuit against IPAB, Doctors Without Borders calls the Ebola outbreak "a complete disaster" and Pfizer becomes the first pharma ...

FDA kind of OKs Lilly/BI's Lantus look-alike

FDA kind of OKs Lilly/BI's Lantus look-alike

Sanofi's patent lawsuit triggered the tentative approval of the Lilly-BI Lantus competitor.

GSK relaunches COPD.com

GSK relaunches COPD.com

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.